List view / Grid view
Anirban Datta, Head of Discovery Biology at Verseon International Corporation, details how recent breakthroughs are bringing once-distant possibilities, such as testing drugs more efficiently and restoring lost organ function through implantation, closer to reality.
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
Novel approaches to brain disorder diagnosis and treatment may be developed following a project to form a map of the mouse hippocampus.
iPS-cell-derived microglia in brain organoids have enabled scientists to understand early brain development and microglia-associated disease.
A recent study led by the Lieber Institute for Brain Development has revealed that over 100 genes associated with the risk of schizophrenia appear to contribute to the development of the illness primarily through their influence on the placenta.
The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
Scientists used human brain organoids to reveal how a genetic mutation associated with a profound form of autism disrupts neural development, and gene therapy tools to recover the gene’s function effectively rescued neural structure and function.
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
Research shows that cells gather more data inside the thalamus than once believed, potentially changing medicines for brain disorders.
Listen along to learn more about drug development for schizophrenia from Dr Sri Gopal, Head of Psychiatry R&D for Janssen!
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
Scientists have imaged the ball-and-chain mechanism using cryogenic electron microscopy and hope their work could be applied in the design of novel therapeutics.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
A key modifier has been identified by researchers in a large fruit fly genetic deletion related to neurodevelopmental disorders such as schizophrenia and autism.
To address the receptor dysfunction associated with several neurological diseases, scientists have provided novel insights into a protein-protein interaction that could lead to more effective treatments.
